1. Home
  2. Knowledge Base
  3. References
  4. BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer’s disease.

BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer’s disease.

Burke RM, Norman TA, Haydar TF, Slack BE, Leeman SE, Blusztajn JK, Mellott TJ (2013) BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 110(48):19567-19572. doi: 10.1073/pnas.1319297110

Summary: During development bone morphogenetic protein 9 (BMP9) induces the cholinergic phenotype in the basal forebrain. The authors investigated the use of BMP9 as a treatment of basal forebrain cholinergic degeneration, such as is seen in Alzheimer’s disease (AD). Transgenic mice displaying AD phenotypes and expressing GFP in cholinergic neurons received icv infusions of BMP9, and several cholinergic markers were assessed. Anti-p75NTR (Cat. #AB-N01) was used in immunoblotting at a 1:3000 dilution to measure p75 levels. The results demonstrate the protective and therapeutic activity of BMP9 on AD symptoms.

Related Products: NGFr (mu p75) Rabbit Polyclonal (Cat. #AB-N01)